Global life sciences company Pressure BioSciences (OTCQB: PBIO) today announced financial results for the first quarter ended March 31, 2018. Among other highlights, Pressure BioSciences reported total revenue of $610,774 for the first quarter of 2018 compared to $551,357 for the same period in 2017, demonstrating an increase of 11%. The company attributes the increase in revenue primarily to its growth in products and services which brought in $585,244 for the first quarter of 2018 compared to $525,998 for the same quarter of 2017, similarly demonstrating an 11% increase. The company also provided a business update and offered limited guidance for the rest of the year.
“In addition to these Q1 2018 financial accomplishments, we reported several noteworthy operational successes as well. First, we negotiated and signed the first biological services contract requiring the use of our patented PreEMT technology platform recently acquired from BaroFold, Inc. Second, we announced a collaboration with ISS, Inc – a major U.S. spectrometry manufacturer whose customers will consequently be able to benefit from the use of our automated pressure generating equipment. Finally, Q1 2018 was the first time that all three of our recently-hired and trained sales directors were in their territories during an entire quarter,” PBIO president and CEO Richard T. Schumacher stated in the news release.
The company is holding a conference call to discuss its first quarter 2018 financial results on Tuesday, May 15, 2018 at 4:30 PM ET. To attend this teleconference, dial (877) 407-8033 for the North America line or (201) 689-8033 for the international using the verbal passcode: PBIO First Quarter 2018 Financial Results Call. The earnings call will also be available for replay for 30 days by dialing (877) 481-4010 for the North America line or (919) 882-2331 for the international line using the ID number 33422.
To view the full press releases, visit http://ibn.fm/KdPma and http://ibn.fm/puNpL
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of the company’s pressure-based technologies in the following areas: (1) the use of its recently acquired PreEMT technology from BaroFold, Inc. to allow entry into the biologics contract research services sector, and (2) the use of its recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
